Drugs.com - Pharma Industry News

ASCO: GLP-1 Receptor Agonists May Reduce Risk for Obesity-Related Cancer, All-Cause Death

WEDNESDAY, May 28, 2025 -- For adults with diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for obesity-related cancer compared with dipeptidyl peptidase-4 (DPP-4) inhibitors, according...

May 28, 2025 - 18:50
 0
ASCO: GLP-1 Receptor Agonists May Reduce Risk for Obesity-Related Cancer, All-Cause Death
WEDNESDAY, May 28, 2025 -- For adults with diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for obesity-related cancer compared with dipeptidyl peptidase-4 (DPP-4) inhibitors, according...
Read More

Tags:

Previous Article

Fierce Biotech Fundraising Tracker '25: AusperBio adds $50M to series B; Grin gr...

Next Article

High-Volume Exercise Tied to Increased Coronary Artery Calcification Score

Related Posts

Exposure to Certain HIV Drugs May Significantly Lower Risk for Alzheimer Disease

Exposure to Certain HIV Drugs May Significantly Lower R...

May 20, 2025  0

Digestive Disease Week, May 3-6

Digestive Disease Week, May 3-6

May 14, 2025  0

Lecanemab for Alzheimer Disease Safe, Feasible in Real-World Practice

Lecanemab for Alzheimer Disease Safe, Feasible in Real-...

May 15, 2025  0